Clinical trials: Diabetes Type II
Cardiovascular Diseases, Atherosclerosis
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Type 2 Diabetes, Insulin Resistance
- Trial name
- NCT04167761
- Testing
- Ertugliflozin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Coronary Heart Disease, Susceptibility to, 5, Prediabetic State
Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
The purpose of this study is to examine whether the use of genetic test information and/or health coaching in patient risk counseling for heart disease and diabetes affect health behaviors and health outcomes in active-duty Air…
- Trial name
- NCT01884545
- Testing
- Health coaching, Genetic risk counseling, Standard risk assessment
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Duke University
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Covid19
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.
- Trial name
- ARCADIA (NCT04516759)
- Testing
- AZD1656
- Where
- 30 sites in Czechia, Romania and 1 more
- Volunteers
- 170 people
- Sponsor
- St George Street Capital
Diabetes
Mechanisms of Glucose Lowering Effect of Colesevelam HCl
The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with…
- Trial name
- NCT00596427
- Testing
- Colesevelam HCL
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Carine Beysen
Type 2 Diabetes Mellitus
Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)
To demonstrate that a focused Emergency Department (ED) intervention for uncontrolled hyperglycemia enables safe and effective glycemic management and reduces emergency room re-visits.
- Trial name
- STEP-DC (NCT01033773)
- Testing
- Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin, Diabetes survival skills self-management education
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Medstar Health Research Institute
Type 2 Diabetes
The Alberta Diet: Effectiveness Study
The study hypothesis is that individuals with type 2 diabetes (T2D), who adhere to the PANDA intervention, will have improved compliance with the nutritional therapy recommendations of the Canadian Diabetes Association.
- Trial name
- NCT01625507
- Testing
- PANDA intervention
- Where
- Canada
- Volunteers
- 73 people
- Sponsor
- University of Alberta
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or…
- Trial name
- ACHIEVE-5 (NCT06109311)
- Testing
- Orforglipron
- Where
- 70 sites in United States, Brazil and 4 more
- Volunteers
- 546 people
- Sponsor
- Eli Lilly and Company
Obstructive Sleep Apnea, Type 2 Diabetes
Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes
The overall goal of the proposed protocol is to rigorously test the hypothesis that CPAP treatment has beneficial effects on glycemic control in patients with both type 2 diabetes (T2DM) and obstructive sleep apnea (OSA).
- Trial name
- CPAP (NCT01136785)
- Testing
- active CPAP Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Chicago
Obesity, Impaired Glucose Tolerance
Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.
- Conditions
- Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
- Trial name
- NCT00413335
- Testing
- Rosiglitazone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
The purpose of the study is to demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on a DPP4(i) with or…
- Trial name
- SOTA-EMPA (NCT03351478)
- Testing
- Sotagliflozin, Empagliflozin
- Where
- 160 sites in United States, Bulgaria and 10 more
- Volunteers
- 770 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in subjects with type 2 diabetes.
- Trial name
- BOOST (NCT02762578)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart
- Where
- 42 sites in China
- Volunteers
- 543 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Obesity
Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
There is substantial clinical evidence regarding the safety and efficacy of currently practiced bariatric surgical techniques to improve metabolic control and/or resolve type 2 diabetes (T2DM) in clinically severe obese patients…
- Trial name
- SLIMM-T2D (NCT01073020)
- Testing
- Allergan Adjustable Gastric Band Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group, Roux-en-Y Gastric Bypass (RYGB) Surgery
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Joslin Diabetes Center
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01619059
- Testing
- Saxagliptin, Dapagliflozin, Metformin IR
- Where
- 83 sites in United States, Canada and 7 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and…
- Trial name
- NCT01106690
- Testing
- Canagliflozin, Sitagliptin, Metformin
- Where
- 83 sites in United States, Canada and 9 more
- Volunteers
- 344 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Treated With Insulin
Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
- Trial name
- NCT06473662
- Testing
- Oral insulin
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Roger New
Diabetes Mellitus, Type 2
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes.
- Trial name
- REALYSE (NCT05035082)
- Testing
- semaglutide, oral glucose-lowering medications (commercially available)
- Where
- 25 sites in United States
- Volunteers
- 1,018 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
- Trial name
- NCT03235050
- Testing
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
- Where
- 119 sites in United States, Bulgaria and 6 more
- Volunteers
- 834 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.